Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
UNI-DUR vs ADDERALL 12.5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
UNI-DUR (theophylline) inhibits phosphodiesterase enzymes, leading to increased intracellular c AMP levels. This causes bronchodilation, anti-inflammatory effects (reduced eosinophil infiltration, decreased cytokine release), and enhanced diaphragmatic contractility. It also acts as a weak adenosine receptor antagonist.
Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.
Treatment of asthma (chronic stable and acute exacerbations),Chronic obstructive pulmonary disease (COPD) maintenance therapy,Apnea of prematurity (off-label),Ureteral colic (off-label)
Attention deficit hyperactivity disorder (ADHD),Narcolepsy (off-label)
200-400 mg orally every 12 hours; maximum 800 mg daily.
5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.
Terminal elimination half-life 24-36 hours; prolonged in renal impairment (up to 90 hours).
The terminal elimination half-life of d-amphetamine is approximately 10–13 hours in adults (range 9–14 h) and 6–8 hours in children. Clinical context: Typically allows twice-daily dosing; extended-release formulations provide 8–12 hours of effect.
Theophylline is primarily metabolized in the liver by cytochrome P450 enzymes CYP1A2 (major) and CYP2E1, CYP3A4 (minor). It undergoes N-demethylation and oxidation to form metabolites (1-methylxanthine, 3-methylxanthine, 1,3-dimethyluric acid). Approximately 10% is excreted unchanged in urine.
Amphetamine and dextroamphetamine are extensively metabolized in the liver via CYP2D6 and other pathways. The primary metabolites are 4-hydroxyamphetamine and 4-hydroxynorephedrine.
Primarily renal (70-80%) as unchanged drug and metabolites; 10-15% fecal.
Approximately 30% of the dose is excreted unchanged in urine; the remainder is metabolized primarily via deamination and oxidation. Renal elimination of unchanged amphetamine is p H-dependent: acidic urine increases elimination, alkaline urine decreases it. Fecal excretion accounts for <5%.
95% bound to albumin.
Approximately 15–20% bound to plasma proteins, primarily albumin.
Vd 0.2-0.3 L/kg; indicates distribution primarily in extracellular fluid.
Mean volume of distribution is 3.5–4.6 L/kg, indicating extensive tissue distribution. Clinical meaning: Large Vd reflects sequestration in tissues (including brain), contributing to prolonged presence.
Oral: 85-95% (immediate-release); 70-80% (extended-release).
Oral bioavailability is highly variable, ranging from 75–100% for immediate-release tablets; food does not significantly affect overall absorption but may delay time to peak concentration. Extended-release capsules have bioavailability approximately 96% relative to immediate-release.
GFR 30-50 m L/min: 200 mg every 12 hours; GFR <30 m L/min: 200 mg every 24 hours; hemodialysis: 200 mg after dialysis.
GFR 15-29 m L/min: reduce dose to 50% of usual; GFR <15 m L/min: use 50% of usual dose; hemodialysis: not removed, avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg every 12 hours; Child-Pugh C: 200 mg every 24 hours.
Child-Pugh A: no adjustment; Child-Pugh B: use 50% of usual dose; Child-Pugh C: avoid use.
5-10 mg/kg orally every 12 hours; maximum 400 mg daily.
Immediate-release: 3-5 years: initial 2.5 mg once daily, increase by 2.5 mg weekly up to 40 mg/day; 6+ years: initial 5 mg once or twice daily, increase by 5 mg weekly up to 40 mg/day. Extended-release: 6-12 years: initial 10 mg once daily, increase by 10 mg weekly up to 30 mg/day; 13-17 years: initial 10 mg once daily, increase by 10 mg weekly up to 40 mg/day.
Initiate at 200 mg every 12 hours; increase cautiously, monitor renal function.
Start at lowest dose (5 mg immediate-release or 10 mg extended-release) and titrate slowly due to increased risk of adverse cardiovascular and CNS effects; monitor for hypertension, tachycardia, and agitation.
WARNING: Life-threatening adverse events, including seizures, cardiac arrhythmias, and respiratory arrest, can occur with theophylline toxicity. Serum theophylline levels must be monitored closely, and dosing adjusted to maintain therapeutic range (5-15 mcg/m L). Concurrent use with other xanthines (e.g., caffeine) is contraindicated.
Adderall has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
Therapeutic drug monitoring required due to narrow therapeutic index. Caution in patients with hepatic impairment, heart failure, pneumonia, elderly, and fever (prolonged half-life). Drug interactions with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) and inducers (e.g., smoking, rifampin). Seizure risk at high levels. Cardiotoxicity (atrial/ventricular arrhythmias).
Risk of abuse and dependence,Serious cardiovascular events including sudden death, stroke, and myocardial infarction,Blood pressure and heart rate increases,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggression,Seizures in patients with seizure disorders,Visual disturbances,Growth suppression in children,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk when used with serotonergic drugs
Hypersensitivity to theophylline or any component. Concurrent use with ephedrine or other xanthines. Active seizure disorder (relative). Uncontrolled cardiac arrhythmias. Severe hepatic impairment.
Known hypersensitivity to amphetamine products or other sympathomimetic amines,Concomitant use with MAOIs or within 14 days of MAOI therapy,Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease including moderate to severe hypertension, advanced arteriosclerosis, symptomatic cardiovascular disease, or tachyarrhythmias
Food does not affect absorption significantly; however, consistent dietary caffeine intake may increase side effects. A high-protein, low-carbohydrate diet can decrease theophylline clearance; avoid drastic dietary changes.
Avoid acidic foods and beverages (e.g., citrus fruits, soda) within 1 hour of administration as they may decrease absorption. High-fat meals may delay absorption of extended-release formulations. Avoid caffeine and other stimulants. Grapefruit juice may increase amphetamine levels.
Pregnancy Category C. First trimester: no adequate studies, potential risk based on animal data. Second and third trimesters: may cause fetal harm including decreased uterine blood flow, growth restriction, and premature labor inhibition. Avoid use unless benefit outweighs risk.
First trimester: Increased risk of congenital malformations, particularly cardiovascular defects (e.g., septal defects) and oral clefts based on amphetamine exposure. Second and third trimesters: risk of preterm delivery, low birth weight, and neonatal withdrawal syndrome (irritability, feeding difficulties, respiratory distress). Premature delivery and growth restriction have been reported.
Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants. Decision to discontinue nursing or drug based on importance to mother.
Contraindicated due to potential for infant toxicity. M/P ratio not established; amphetamine is excreted into breast milk in small amounts but may accumulate in breastfeeding infants. Adverse effects include irritability, poor feeding, and decreased weight gain.
No standard dose adjustments. Increased clearance and volume of distribution during pregnancy may require dose titration based on clinical response and serum drug levels if applicable.
Pharmacokinetics altered: increased hepatic metabolism and renal clearance in pregnancy may reduce amphetamine exposure; however, safety data do not support dose adjustment. Use lowest effective dose only if necessary; consider alternative non-amphetamine therapies.
UNI-DUR (theophylline extended-release) requires monitoring of serum theophylline concentrations to maintain efficacy and avoid toxicity; therapeutic range is 5-15 mcg/m L. Avoid use in patients with active peptic ulcer disease or seizure disorders. Dosage adjustments needed in hepatic impairment, heart failure, and with concurrent use of drugs that affect CYP1A2 and CYP3A4.
ADDERALL 12.5 mg is a fixed-dose combination of amphetamine and dextroamphetamine. Monitor for cardiovascular events, especially in patients with pre-existing heart conditions. Onset of action occurs within 30-60 minutes; duration of action is approximately 4-6 hours. Avoid late afternoon doses to prevent insomnia. Use with caution in patients with a history of drug abuse. May cause growth suppression in children; monitor height and weight. Do not crush or chew extended-release capsules.
Take UNI-DUR exactly as prescribed, at the same time each day, with or without food.,Do not crush or chew the tablets; swallow whole.,Avoid smoking and limit caffeine intake as they can alter theophylline levels.,Report symptoms of toxicity such as nausea, vomiting, insomnia, palpitations, or seizures.,Do not change brands or formulations without consulting your healthcare provider.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Swallow the capsule whole; do not chew, crush, or open it.,Avoid alcohol while taking this medication.,Do not drive or operate machinery until you know how this medication affects you.,Report any chest pain, shortness of breath, or fainting to your doctor immediately.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about UNI-DUR vs ADDERALL 12.5, answered by our medical review team.
UNI-DUR is a Methylxanthine Bronchodilator that works by UNI-DUR (theophylline) inhibits phosphodiesterase enzymes, leading to increased intracellular c AMP levels. This causes bronchodilation, anti-inflammatory effects (reduced eosinophil infiltration, decreased cytokine release), and enhanced diaphragmatic contractility. It also acts as a weak adenosine receptor antagonist.. ADDERALL 12.5 is a CNS Stimulant that works by Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between UNI-DUR and ADDERALL 12.5 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of UNI-DUR is: 200-400 mg orally every 12 hours; maximum 800 mg daily.. The standard adult dose of ADDERALL 12.5 is: 5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between UNI-DUR and ADDERALL 12.5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. UNI-DUR is classified as Category C. Pregnancy Category C. First trimester: no adequate studies, potential risk based on animal data. Second and third trimesters: may cause fetal harm including decreased uterine blood. ADDERALL 12.5 is classified as Category C. First trimester: Increased risk of congenital malformations, particularly cardiovascular defects (e.g., septal defects) and oral clefts based on amphetamine exposure. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.